| Publikacja | Impact Factor |
|---|---|
| 2014 | |
| Graham S, et al. incl. Gaciong Z among 253 co-authors. Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. PLoS One. 2014 Nov 26;9(11):e113447. | 3,5 |
| Lewandowski J, Siński M, Puchalska L, Symonides B, Gaciong Z. Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels. J Am Soc Hypertens. 2014 Oct;8(10):715-23. | 2,6 |
| Pullicino PM, et al. incl. Gaciong Z among >500 co-authors. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. Cerebrovasc Dis. 2014;38(3):176-81. | 3,6 |
| Rutkowski M, Bandosz P, Czupryniak L, Gaciong Z, Solnica B, Jasiel-Wojculewicz H, Wyrzykowski B, Pencina MJ, Zdrojewski T. Prevalence of diabetes and impaired fasting glucose in Poland–the NATPOL 2011 Study. Diabet Med. 2014 Dec;31(12):1568-71. | 3,0 |
| Halperin JL, et al. incl. Gaciong Z among >1000 co-authors. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-46. | 14,9 |
| Orlowska-Baranowska E, Gora J, Baranowski R, Stoklosa P, Gadomska vel Betka L, Pedzich-Placha E, Milkowska M, Koblowska MK, Hryniewiecki T, Gaciong Z, Placha G. Association of the common genetic polymorphisms and haplotypes of the chymase gene with left ventricular mass in male patients with symptomatic aortic stenosis. PLoS One. 2014 May 13;9(5):e96306. | 3,5 |
| Sinski M, Lewandowski J, Przybylski J, Zalewski P, Symonides B, Abramczyk P, Gaciong Z. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients. Hypertens Res. 2014 Sep;37(9):858-62. | 2,9 |
| Symonides B, Holas P, Schram M, Śleszycka J, Bogaczewicz A, Gaciong Z. Does the control of negative emotions influence blood pressure control and its variability? Blood Press. 2014 Dec;23(6):323-9. | 1,6 |
| Meyer G, et al. incl. Gaciong Z among 129 co-authors. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. | 54,4 |
| Schulman S, et al. incl. Gaciong Z among >232 co-authors. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72 | 14,9 |
| 2013 | |
| Gaciong Z, Siński M, Lewandowski J. Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep. 2013 Dec;15(6):559-74. | 3,9 |
| Lewandowski J, Sinski M, Symonides B, Korecki J, Rogowski K, Judycki J, Sieczych A, Możeńska O, Gaciong Z. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. Urology. 2013 Sep;82(3):660-5. | 2,1 |
| Zdrojewski T, Rutkowski M, Bandosz P, Gaciong Z, Jędrzejczyk T, Solnica B, Pencina M, Drygas W, Wojtyniak B, Grodzicki T, Piwoński J, Wyrzykowski B. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013;71(4):381-92. | 0,5 |
| Antikainen RL, et al. incl. Gaciong Z among >250 co-authors. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in the Hypertension in the Very Elderly Trial. J Hypertens. 2013 Jun;31(6):1224-32 | 4,2 |
| Schulman S, et al. incl. Gaciong Zamong >450 co-authors. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. | 54,4 |
| Agnelli G, et al. incl. Gaciong Z among >400 co-authors. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. | 54,4 |